Tumor Burden and Clinical Benefit Assessment in Immunotherapy Clinical Trials

xtalks logo


This webinar will give an overview of endpoint assessment as it relates to RECIST, irRC, and clinical benefit in the setting of cancer immunotherapy. Recommendations on when and how to apply each criterion will be reviewed as will case histories illustrating the clinical decision-making needed to determine if a patient should continue treatment.

Ad Reference ID: 60657b7391508aca

No Tags


Report problem

Processing your request, Please wait....

Leave a Reply